Navigation Links
TPI Receives GMP Certification for JCM Facility

CHENGDU, China, Jan. 18, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced the Company has received the Good Manufacturing Practice (GMP) certification for its 250-ton Jiangchuan Macrolide Facility (JCM) designated as "CHUAN M0799" valid through the period of December 31, 2011 until December 31, 2015.

Detailed information of the GMP certification for JCM facility can also be found in the official site of Sichuan Food and Drug Administration ( (Chinese version)).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:

About GMP

Good manufacturing practice (GMP) are a set of comprehensive quality management system required for pharmaceutical manufacturing covering the manufacture and testing of pharmaceuticals including APIs, diagnostics, foods, pharmaceutical products, and medical devices. GMPs are guidelines that outline the aspects of production that ensure the quality of a product.

GMP certification is conducted based on several underlying basic principles: 1) Clearly defined manufacturing processes that are controlled with critical processes validated to ensure consistency and compliance with specifications during the production; 2) Good Documentation Practices; 3) Operators are trained to carry out and document procedures; 4) Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were carried out and that ensure the quantity and quality of the drug; 5) Records of manufacture and distribution that trace the complete history of a batch are retained in a comprehensible and accessible form. 6) The distribution of the drugs minimizes any risk to their quality; 7) A system is available for recalling any batch of drug from sale; 8) Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit:, or email
Tel: +86-28-8551-6696 (Chengdu, China)
     +86-134-3655-0011 (China)

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
2. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
3. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. BioNeutral Group Receives $400,000 in Equity Financing
6. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
9. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
10. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
11. Watsons Generic Yaz(R) Receives FDA Approval
Post Your Comments:
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... 2015  Rebiotix Inc. today announced that U.S. ... lead Microbiota Restoration Therapy (MRT) RBX2660 as a ... Clostridium difficile (C diff) infection, a challenging ... deaths in the U.S. annually. 1 Rebiotix ... founded to revolutionize the treatment of debilitating GI ...
(Date:10/12/2015)... , October 12, 2015 ... Dario™ Diabetes Management Solution, today announced its Medical Director, ... case study at MobiHealth,s 5th EAI International Conference ... "Transforming healthcare through innovations in mobile and wireless technologies," ... England from October 14 - 16, 2015. ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in consumer ... the world’s first amphibious fitness tracker that seeks to meet the needs of multi-sport ... heart rate monitoring both in water and on land, making it the ...
Breaking Biology Technology:
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/26/2015)... 26th, 2015  Results of a TactioRPM pilot ... today at the Stanford Medicine X Conference. In ... Dashboards, Connected Health Devices and Pharmacogenomics", Roger ... will explain how senior patients equipped with connected ... pharmacist via the TactioRPM remote patient monitoring platform ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):